SELLAS Life Sciences Group, Inc. (SLS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2M 4M 6M Q1 '12: 2.8M Q2 '12: 3.4M Q3 '12: 0 Q4 '12: 1.4M Q1 '13: 0 Q2 '13: 0 Q3 '13: 1.2M Q4 '13: 1.4M Q1 '14: 2.2M Q2 '14: 2.3M Q3 '14: 1.6M Q4 '14: 3.2M Q1 '15: 2.8M Q2 '15: 3.4M Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 1.9M Q1 '21: 5.7M Q2 '21: 1.9M Q3 '21: 0 Q4 '21: 0 Q1 '22: 1M Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '12 Q2 '13 Q2 '14 Q2 '15 Q4 '20 Q4 '21 Q4 '22 Q4 '23

Gross Profit Quarterly

0 1M 2M 3M Q1 '12: 2.4M Q2 '12: 2.9M Q3 '12: 0 Q4 '12: 1.2M Q1 '13: 2.4M Q2 '13: 2.9M Q3 '13: 869K Q4 '13: 1.2M Q1 '12 Q2 '12 Q3 '12 Q4 '12 Q1 '13 Q2 '13 Q3 '13 Q4 '13

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '14: -10.6M Q4 '14: -9.7M Q1 '15: -8.9M Q2 '15: -9.1M Q3 '15: -8.6M Q4 '15: -7.6M Q1 '16: -9M Q2 '16: -9.3M Q3 '16: -6.5M Q4 '16: 8.7M Q1 '17: -5.1M Q2 '17: -4.9M Q3 '17: -4.5M Q4 '17: -8.6M Q1 '20: -4.1M Q2 '20: -4.3M Q3 '20: -4.5M Q4 '20: -4.2M Q1 '21: -2.2M Q2 '21: -4.5M Q3 '21: -7M Q4 '21: -11.6M Q1 '22: -16.7M Q2 '22: -8.6M Q3 '22: -7.1M Q4 '22: -9.4M Q1 '23: -11.3M Q2 '23: -9.1M Q3 '23: -9.4M Q4 '23: -8.2M Q1 '24: -9.6M Q2 '24: -7.6M Q3 '24: -7.3M Q4 '24: -6.9M Q1 '25: -6.1M Q2 '25: -6.9M Q3 '25: -7.1M Q4 '25: -8.3M Q1 '26: -9.3M Q2 '26: -10.6M Q3 '15 Q4 '16 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '16: -6.9M Q4 '16: 352K Q1 '17: -4.6M Q2 '17: -5.9M Q3 '17: -4.5M Q4 '17: -8.8M Q1 '18: -8M Q2 '18: -6.1M Q3 '18: -290K Q4 '18: -13.3M Q1 '19: -4.5M Q2 '19: -3.1M Q3 '19: -4.2M Q4 '19: -7.4M Q1 '20: -4.1M Q2 '20: -4.4M Q3 '20: -4.5M Q4 '20: -3.7M Q1 '21: -2.4M Q2 '21: -4.6M Q3 '21: -7.1M Q4 '21: -6.6M Q1 '22: -16.7M Q2 '22: -8.4M Q3 '22: -7M Q4 '22: -9.1M Q1 '23: -11.1M Q2 '23: -8.8M Q3 '23: -9.3M Q4 '23: -8.1M Q1 '24: -9.6M Q2 '24: -7.5M Q3 '24: -7.1M Q4 '24: -6.7M Q1 '25: -5.8M Q2 '25: -6.6M Q3 '25: -6.8M Q4 '25: -7.7M Q1 '26: -8.4M Q2 '26: -9.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 200K 400K 600K Q3 '12: 0 Q4 '12: 0 Q1 '13: 0 Q2 '13: 0 Q3 '13: 258K Q4 '13: 262K Q1 '14: 331K Q2 '14: 347K Q3 '14: 247K Q4 '14: 478K Q1 '15: 393K Q2 '15: 468K Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 100K Q2 '21: 100K Q3 '21: 0 Q4 '21: 0 Q1 '22: 100K Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q1 '13 Q2 '14 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '16: -12.2M Q4 '16: -5.5M Q1 '17: -3.8M Q2 '17: -3M Q3 '17: -2.4M Q4 '17: -1.7M Q1 '18: -5.4M Q2 '18: -6.3M Q3 '18: -14.2M Q4 '18: -4.6M Q1 '19: -5M Q2 '19: -4.7M Q3 '19: -3.8M Q4 '19: -4.2M Q1 '20: -6.8M Q2 '20: -3.4M Q3 '20: -3.6M Q4 '20: 3.4M Q1 '21: -10.3M Q2 '21: -4.9M Q3 '21: -5.9M Q4 '21: -5M Q1 '22: -7.2M Q2 '22: -5.8M Q3 '22: -5.7M Q4 '22: -5.2M Q1 '23: -12.1M Q2 '23: -7.6M Q3 '23: -6.9M Q4 '23: -4.8M Q1 '24: -10.8M Q2 '24: -9.7M Q3 '24: -7.8M Q4 '24: -7.2M Q1 '25: -9.1M Q2 '25: -7.3M Q3 '25: -7.1M Q4 '25: -4.9M Q1 '26: -8.8M Q2 '26: -7.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '10: -2.2M Q4 '10: -1.9M Q1 '11: -3.1M Q2 '11: -4.1M Q3 '11: -3.4M Q4 '11: -4.2M Q1 '12: -4.9M Q2 '12: -6.7M Q3 '12: -4.2M Q4 '12: -5.2M Q1 '13: -5.3M Q2 '13: -7.6M Q3 '13: -8.1M Q4 '13: -8.7M Q1 '14: -8.1M Q2 '14: -13M Q3 '14: -11.1M Q4 '14: -10.7M Q1 '15: -11.6M Q2 '15: -11.9M Q3 '15: -9.5M Q4 '15: -15.4M Q1 '16: -13.2M Q2 '16: -11.5M Q3 '16: -12.2M Q4 '16: -5.5M Q4 '10 Q4 '11 Q4 '12 Q4 '13 Q4 '14 Q4 '15 Q4 '16

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '12: 67.2M Q2 '13: 83.7M Q2 '15: 161.4M Q2 '16: 9.3M Q2 '17: 37.4M Q2 '20: 6.7M Q3 '20: 8.4M Q1 '21: 14.9M Q2 '21: 15.3M Q3 '21: 15.9M Q1 '22: 15.9M Q2 '22: 20.3M Q3 '22: 20.6M Q1 '23: 23.5M Q2 '23: 28.3M Q3 '23: 28.4M Q1 '24: 44.8M Q2 '24: 57.6M Q3 '24: 68.3M Q1 '25: 87.8M Q2 '25: 98.6M Q3 '25: 108.4M Q1 '26: 172.5M Q2 '26: 189.2M Q2 '15 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q3 '14: -0.76 Q4 '14: -6.13 Q1 '15: -6.19 Q2 '15: -6.12 Q3 '15: -6.18 Q4 '17: -12.00 Q1 '18: -10.04 Q2 '18: -11.08 Q3 '18: -35.56 Q4 '18: -49.97 Q1 '19: -59.42 Q2 '19: -64.49 Q3 '19: -40.42 Q4 '19: -10.92 Q1 '20: -0.46 Q2 '20: 5.21 Q3 '20: 7.36 Q4 '20: -2.13 Q1 '21: -1.63 Q2 '21: -1.27 Q3 '21: -1.19 Q4 '21: -1.33 Q1 '22: -2.22 Q2 '22: -2.33 Q3 '22: -2.22 Q4 '22: -2.23 Q1 '23: -1.65 Q2 '23: -1.55 Q3 '23: -1.54 Q4 '23: -1.36 Q1 '24: -1.10 Q2 '24: -0.92 Q3 '24: -0.69 Q4 '24: -0.52 Q1 '25: -0.38 Q2 '25: -0.32 Q3 '25: -0.28 Q4 '25: -0.25 Q1 '26: -0.23 Q2 '26: -0.21 Q3 '15 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.